06/12/2018 08:30:00

SpeeDx Receives CE-IVD Mark for ResistancePlus® GC Gonorrhea Test

SYDNEY, Australia, Dec. 06, 2018 (GLOBE NEWSWIRE) -- SpeeDx Pty. Ltd. announced today it has received CE-IVD marking for its ResistancePlus® GC assay that detects both the sexually transmitted infection (STI) N. gonorrhoeae, and sequences in the gyrA gene of the bacteria associated with susceptibility to ciprofloxacin (Cipro), a previously used front-line antibiotic treatment. Currently, ceftriaxone ̶ a painful intramuscular injection ̶ combined with azithromycin, is the front-line treatment for gonorrhea in the U.S. However, ceftriaxone represents one of the last remaining antibiotics used for multi-drug-resistant infections and needs to be utilized sparingly so as not to increase resistance to the drug. Already, there are strains of gonorrhea that are resistant to this treatment.

SpeeDx’s new test will allow doctors to confidently and cost-effectively treat up to 70% of gonorrhea infections with a single oral dose of ciprofloxacin because the test establishes disease susceptibility to ciprofloxacin prior to prescribing.

"The ResistancePlus GC test is the first innovation in gonorrhea treatment in decades,” said Dr. Jeffrey Klausner, Professor of Medicine and Public Health at David Geffen School of Medicine and Fielding School of Public Health, University of California, Los Angeles. “With the continued spread of multi-drug gonorrhea, this test can make a real difference.”

Recent surveillance data shows that susceptibility to ciprofloxacin is as high as 70% in some regions and greater than 50% across the majority of countries contributing surveillance data.1-4 In response to the clear utility of ciprofloxacin, the British Association of Sexual Health and HIV (BASHH) have recently drafted new gonorrhea management guidelines that include the preferential use of ciprofloxacin over ceftriaxone if antimicrobial susceptibility testing results are available prior to treatment.5

“We used a similar test at UCLA in Los Angeles and found that doctors liked the test and were much more likely to prescribe a safer and simpler medicine like oral Cipro tablets instead of using injections like Ceftriaxone,” reports Dr. Klausner.

“ResistancePlus GC is an important next step in our ResistancePlus portfolio and is a welcome addition in managing the extensive antibiotic resistance in N. gonorrhoeae infections,” said Colin Denver, CEO for SpeeDx. “We are already seeing high interest in this test with its clear role in maintaining stewardship of the limited antibiotics still available to treat gonorrhea.”

Resistance

Plus GC is the first commercially available molecular test* providing ciprofloxacin susceptibility information and is well placed to support current laboratory molecular testing workflows. “If more doctors use the ResistancePlus GC assay, patients will have a better choice when it comes to treatment and we might make a big difference in controlling antibiotic resistant gonorrhea,” adds Dr. Klausner. “Untreatable gonorrhea is a real threat ̶ use of the ResistancePlus GC assay might stop that.''

*available where CE-mark is accepted, not available in the U.S. or A.U.

About Gonorrhea

N. gonorrhoeae is a bacterium causing gonorrhea, a sexually transmitted infection most frequently causing urethritis in men and cervicitis in women. Gonorrhea can result in infertility or ectopic pregnancy and also increases the risk of acquiring other STIs, including HIV. Transmission from infected mothers to newborns during birth can result in gonococcal conjunctivitis, an infection in the eye (ophthalmia neonatorum).

Prevalence and incidence rates of gonorrhea have been increasing around the world, with corresponding increasing rates of resistance to commonly used antibiotics.6 Recent studies suggest N. gonorrhoeae is threatening to become untreatable as resistance continues to develop against all known antibiotic treatments.6 The currently recommended front-line treatment, ceftriaxone, is the last known effective antibiotic, and several extensively drug resistant strains have now been isolated exhibiting resistance to this and many other available treatments.7,8 Global management strategies for antimicrobial resistance highlight gonorrhea as a priority infection to manage, with more effective use of diagnostic tools listed as a key focus for future development.9

About ResistancePlus®

Resistance

Plus

® kits are multiplex qPCR tests for detection of infectious diseases and antibiotic resistance markers, respectively. Powered by proprietary PlexZyme® and PlexPrime® technologies, the product line offers high multiplexing capability for better, more streamlined infectious disease management. ResistancePlus test offer more than detection, supporting resistance guided therapy by providing actionable information for laboratories and clinicians alike.

About SpeeDx

Founded in 2009, SpeeDx is an Australian-based private company with offices in London and the US, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see https://plexpcr.com

References

1. Harris SR et al. Lancet Infect Dis Published online May 15th 2018.

2. Lahra MM et al. Australian Gonococcal Surveillance Programme annual report, 2015

3.Heffernan H et al. Antimicrobial resistance and molecular epidemiology of gonococci in NZ, 2014-5

4.  Kirkcaldy RD et al. MMWR Surveillance Summaries July 15, 2016 / 65(7);1–19

5. Fifer H. et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae (Draft).

6. Unemo, M. & Jensen, J.S. 2016. Nat. Rev. Urol..268. Published online 10 Jan 2017. doi:10.1038/nrurol

7. PHE Health Protection Report Volume 12, Number 11. 2018

8. AU DoH Media Statement April17th 2018.

9. Rapid Risk Assessment 7 May 2018. Stockholm: ECDC; 2018.

  

Contacts

 

Asia Pacific and EuropeUnited States
  
Global Marketing ManagerRCI Healthcare Public Relations
Madeline O’DonoghueRick Roose

madelineo@speedx.com.au

roi.roose@gmail.com

+61 2 9209 4170+1 415 202 4445

 

 

SpeeDx-SMALL--Master.png

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
11 Dec
 
mne: Short - når det lykkedes!    Forbyd short totalt. - Det er kursmanipulatorernes og finansforbr..
67
10 Dec
VELO
Når man følger Veloxis-debatten, og det hr jeg gjort i mange, mange år - også da den hed LCP, så går..
31
01:13
I:DAX
DAX optrend target 15.000   Dax har nu udviklet sig som korrektionstrenden plejer de seneste mange å..
29
16 Dec
VELO
  Når VELO bliver samlinger med en lottokupon, eller beskrevet, som forretning der er fundamentalt u..
29
13 Dec
PNDORA
"Carnegie bestemmer pandoras aktiekurs, basta!!Sådan udtaler en chefanalytiker sig.Carnegie har samm..
27
15 Dec
PNDORA
Det er altid mere enkelt vurderer, hvad ledelsen i Pandora burde have gjort, når man kender effekten..
26
12 Dec
PNDORA
Stornedtur: Din profil er da lige oprettet for 6 dage siden 😎 er du en troll/bandit 😂 Stornedtur A..
23
13 Dec
PNDORA
Din skrivelse er intet andet end en omgang sludder. Det rene nonsens. Det er simpelthen ubegribelig..
17
16 Dec
OMXC25
Næh, det kan blive meget før end om 50 år. Min grænse for en tabt kamp mod CO2 var permafrosten. Den..
16
13 Dec
DANSKE
CBS undersøgte muligheden for at droppe Danske Bank helt: Vi skal fare med lempe Kilde: https://fina..
16

HSBC Bank Plc : Form 8.5 (EPT/RI) - Lonmin PLC

22/02/2018 10:54:53
FORM 8.5 EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Name of exempt principal trader: HSBC BANK PLC (b) Name of offeror/offeree i..

Rathbone Brothers Plc : Preliminary announcement of 2017 results

22/02/2018 07:00:19
Funds under management up 14.3% to £39.1 billionThis is a preliminary statement of annual results published in accordance with FCA Listing Rule 9.7A. It covers the year ended 31 December 2017. Mark Nicholls, Chairman of Rathbone Brothers Plc, said: "UK and global investment markets performed well in 2017, with some indices reaching record levels towards the end of the year. This outcome has b..

Elliott Capital Advisors, L.P : Form 8.3 - GKN Plc

Related news
21/02/2018 15:25:10
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Elliott Capital Advisors, L.P. (for itself and related general partners ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of EIX, ATUS, BA, CMCM and TDOC
2
RxWellness Spine & Health is now offering Physical Therapy Services in Herndon, Reston, Sterling and Surrounding Areas
3
VALNEVA Initiates Phase 2 Clinical Development For Its Lyme Disease Vaccine Candidate
4
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OZK, FIT, RYAAY, MDR and PPDF
5
CLASS ACTION UPDATE for CWH, HON and TX: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Berlingske Media 2018  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
17 December 2018 08:45:41
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20181207.1 - EUROWEB4 - 2018-12-17 09:45:41 - 2018-12-17 08:45:41 - 1000 - Website: OKAY